Co-led by Rodrigo Toledo and Elena Garralda, IMMUNOMICS-VHIO is a platform for the discovery and validation of liquid biopsy biomarkers…
Rodrigo Toledo
Results from the LITESPARK-015 open-label, multicohort phase 2 trial show that hypoxia-inducible factor-2 alpha inhibitor belzutifan achieves durable antitumor activity…
Results of a VHIO led study show that up to 90% of chronically hypoxic patients have an EPAS1 alteration in…
The ultrasensitive liquid biopsy technique applied in this work is based on the sequencing of the entire tumour genome from…
Reported today at the ESMO Congress 2023 in Madrid, results of a VHIO prospective study point to the promise of…
Liquid biopsy is increasingly stepping up as a non-invasive approach in detecting and tracking circulating tumor DNA (ctDNA) in blood…
Published in Nature Medicine, a VHIO-led study has unveiled a new predictive biomarker of response to anti-BRAF/EGFR combinatory therapy in…
Commonly used liquid biopsy techniques test for tumour mutations in a single gene or in a specific set of genes…
